MESOBLAST LTD- SPON ADR (MESO)
US5907174016 - ADR
MESOBLAST LTD- SPON ADR
NASDAQ:MESO (12/19/2024, 8:02:21 PM)
Premarket: 13.7 -3.06 (-18.26%)16.76
+4.51 (+36.82%)
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
Company Info
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000
P: 61396396036
CEO: Silviu Itescu
Employees: 73
Website: https://www.mesoblast.com/
MESO News
21 hours ago - ChartmillThe market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
a day ago - ChartmillDiscover the top movers in Thursday's pre-market session and stay informed about market dynamics.Wondering what's happening in Thursday's pre-market session? Find an overview in this article.
a day ago - Yahoo FinanceMesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock SurgesOn Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents. Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cell
a day ago - Mesoblast LimitedMesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyRYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months...
2 days ago - Investor's Business DailyTop-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition ApprovalThe company will soon launch Ryoncil for children at least 2 months old with acute graft versus host disease.
2 days ago - Mesoblast LimitedMesoblast to be Added to Nasdaq Biotechnology IndexNEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
MESO Twits
Here you can normally see the latest stock twits on MESO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
